Prominent Hypercoagulability Associated With Inflammatory State Among Cancer Patients With SARS-CoV-2 Infection
Abnormal coagulation parameters and potential benefits of anticoagulant therapy in general population with novel coronavirus pneumonia (COVID-19) have been reported. However, limited data are available on cancer patients. Coagulation indexes and inflammation parameters in 57 cancer patients with SARS-CoV-2 infection with different severity were retrospectively analyzed. We found that D-dimer levels were increased in 33 patients (57.9%, median: 790 ng/mL). Compared with ordinary type patients, severe and critical ill patients had decreased MPV values (P = 0.006), prolonged PT (median: 13.3 vs. 11.5 vs. 11.4 s, P < 0.001), significant higher D-dimer levels (median: 2,400 vs. 940 vs. 280 ng/mL, P < 0.001), higher PCT levels (median: 0.17 vs. 0.055 vs. 0.045 ng/mL, P = 0.002), higher IL-6 (median: 20.6 vs. 2.3 vs. 3.0 pg/mL, P = 0.040), and decreased PaO2 (median: 68 vs. 84 vs. 96 mm Hg, P < 0.001). Importantly, three patients, one severe and two critical ill type, with increased D-dimer survived after anticoagulant therapy with continuous heparin infusion. Increased D-dimer levels positively correlated with increased PCT levels (r = 0.456, P = 0.002) and IL-6 levels (r = 0.501, P = 0.045). A negative correlation between D-dimer levels and PaO2 levels (r = −0.654, P = 0.021) were also existed. Cancer patients with COVID-19 showed prominent hypercoagulability associated with severe inflammation, anticoagulation therapy might be useful to improve the prognosis and should be immediately used after the onset of hypercoagulability.
CITE THIS COLLECTION
REFERENCES
- https://doi.org//10.1056/NEJMoa2001017
- https://doi.org//10.1016/S0140-6736(20)30251-8
- https://doi.org//10.1056/NEJMoa2001316
- https://doi.org//10.1016/S0140-6736(20)30154-9
- https://doi.org//10.2807/1560-7917.ES.2020.25.4.2000058
- https://doi.org//10.1056/NEJMc2001272
- https://doi.org//10.1016/S1470-2045(20)30096-6
- https://doi.org//10.1001/jamaoncol.2020.0980e200980
- https://doi.org//10.1001/jama.2020.1585
- https://doi.org//10.1016/S0140-6736(20)30566-3
- https://doi.org//10.1111/jth.14768
- https://doi.org//10.1016/S2213-2600(20)30216-2
- https://doi.org//10.1016/j.jvs.2018.09.062
- https://doi.org//10.3760/cma.j.issn.0253-2727.2017.05.001
SHARE
Usage metrics
Read the peer-reviewed publication
![Frontiers in Oncology](https://s3-eu-west-1.amazonaws.com/876az-branding-figshare/frontiers/logo.png)